The Toledo Blade recently ran an interesting piece about the dangerous
side effects of Yaz, Yasmin and Ocella birth control pills.
Despite its rank as the top-selling
birth control in the United States, Yaz has been found to increase the risk of
blood clots more than other older birth control pills.
All birth control pills carry the
risk of certain side effects, including nausea, weight gain, depression and
blood clots, which is why the FDA required all birth control brands to change
their warning labels this past April. However, pills containing the hormone drospirenone
pose a two- to three-times higher risk to women than traditional birth control
pills do. Currently, the only pills on the market that contain drospirenone are
Yaz, Yasmin, Ocella, BeYaz and their generics.
The article also went on to discuss
the 11,000 lawsuits that are currently pending nationwide, as women who have
suffered severe injuries while taking Yaz, Yasmin and Ocella have filed claims against
Bayer, the drugs’ manufacturer.
The lawyers in our office are very
familiar with these claims, as we represent hundreds of women who are facing
the same medical problems. Blood clots, stroke and DVT are just a few of the
serious health issues that we are assisting the women with, as we continue to
work the cases that have been consolidating into Multi-District Litigation.
More lawsuits are expected, and
according to a Businessweek article
last month, Bayer is said to be paying out $100 million to settle 500 of the Yaz
birth control injury cases.
If you have any questions regarding
this settlement, please do not hesitate to contact our office and speak with
Attorney Zachary Murry. Also, if you are considering filing a claim for
injuries suffered from the development of a blood clot while taking Yaz,
Yasmin, Ocella, or any Drospirenone-containing oral contraceptive, and would
like to know more about the litigation, potential settlement, or receive a free
case evaluation, please contact us at (888)841-9623 or via email at Anneke@toledolaw.com.
No comments:
Post a Comment